Metformin for pancreatic cancer

The Lancet Oncology

Volumn 16, Issue 7, 2015, Pages 748-749

  Aung, Kyaw L ^a   Moore, Malcolm J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GLUCOSE; INSULIN; INSULIN RECEPTOR; METFORMIN; SOMATOMEDIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER RISK; CLINICAL OBSERVATION; COHORT ANALYSIS; DRUG TOLERABILITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MORTALITY; NOTE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; FEMALE; MALE; PANCREATIC NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; METFORMIN; PANCREATIC NEOPLASMS;

EID: 84937518651     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00029-7     Document Type: Note

References (12)

1. Yin M, Zhou J, Gorak EJ, Quddus F Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013, 18:1248-1255.
2. Wang Z, Lai ST, Xie L, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014, 106:19-26.
3. Kordes S, Pollack MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2015, published online June 9. http://dx.doi.org/10.1016/S1470-2045(15)00027-3.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
5. Ryan DP, Hong TS, Bardeesy N Pancreatic adenocarcinoma. N Engl J Med 2014, 371:1039-1049.
6. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691-1703.
7. Pollak M Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
8. Owen MR, Doran E, Halestrap AP Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000, 348:607-614.
9. Vazquez F, Lim JH, Chim H, et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23:287-301.
10. Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013, 23:302-315.
11. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
12. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007, 67:6745-6752.